Q3 Presentation 2022

We create value and contribute to improved quality of life in Life Science

2

MedCap | An active investor in Life Science companies

MedTech Business Area

Sales by Segment (MSEK)

Geographies

5%

35%

19%

Sweden

Nordic

1 046

52%

Europe

65%

24%

RoW

Specialty Pharma Business Area

Employees

375

Listed on Stockholm

Nasdaq Mid Cap

MedTech Specialty Pharma

3

Highlights Q3

  • Sales growth by 19%
  • EBITDA increased by 32%
    excluding one-time effects of 20 mSEK this quarter and 11.8 mSEK last year
  • Good performance in both business areas
  • Strengthened margin (29% EBITDA-margin (21%) after excluding one-time effects)
  • Solid balance sheet; Net Debt / EBITDA ratio
    • IFRS16: 0.2 (0.9)
    • Excl IFRS16: -0.5(-0.1)

Q3 2022

Net Sales

241.5

+19%

(MSEK)

EBITDA

69.7

+41%

(MSEK)

EBITDA-

28.9%

+4.4 ppt

margin

4

Sales and EBITDA by quarter

Net sales per quarter (MSEK)

+19%

300

258

263

284

233

242

250

227

223

200

211

206

209

202

183

188

186

175

200

173

166

160

150

100

50

0

Q1

Q2

Q3

Q4

*

Q2

Q3

Q4

Q1

Q2

Q3

Q4

Q1

Q2

Q3

Q4

Q1

Q2

Q3

Q1

18

19

20

EBITDA per quarter (MSEK)

+41%

80

67

70

70

59

60

56

50

50

50

46

41

41

41

36

38

35

40

31

27

30

22

19

20

17

20

10

0

Q1

Q2

Q3

Q4

*

Q2

Q3

Q4

Q1

Q2

Q3

Q4

Q1

Q2

Q3

Q4

Q1

Q2

Q3

Q1

18

19

20

  • Q3 2017/18: two months
  • IFRS16 incl. from Q1 2019

Q3

YTD

R12

Net Sales

+19%

+20%

+18%

growth

EBITDA

+41%

+36%

+36%

growth

EBITDA-

29%

24%

24%

margin

  • One-timeeffects of 20.0 mSEK in Q3 2022 and 11.8 mSEK in Q3 2021

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

MedCap AB published this content on 28 October 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 October 2022 04:42:05 UTC.